Buprenorphine
- Generic Name
- Buprenorphine
- Brand Names
- Belbuca, Brixadi, Buprenex, Buprenorphine, Butrans, Sublocade, Suboxone, Subutex, Zubsolv, Buvidal, Sixmo
- Drug Type
- Small Molecule
- Chemical Formula
- C29H41NO4
- CAS Number
- 52485-79-7
- Unique Ingredient Identifier
- 40D3SCR4GZ
- Background
Buprenorphine is a weak partial mu-opioid receptor agonist and a weak kappa-opioid receptor antagonist used for the treatment of severe pain. It is also commonly used as an alternative to methadone for the treatment of severe opioid addiction. Buprenorphine is commercially available as the brand name product Suboxone which is formulated in a 4:1 fixed-dose c...
- Indication
Buprenorphine is available in different formulations, such as sublingual tablets, buccal films, transdermal films, and injections, alone or in combination with naloxone.
...
- Associated Conditions
- Opioid Dependence, Severe Pain, Moderate Opioid Dependence, Moderate Pain, Severe Opioid Dependence
- Associated Therapies
- -
Incomplete Response in Late-Life Depression: Getting to Remission With Buprenorphine
- Conditions
- Interventions
- First Posted Date
- 2014-06-27
- Last Posted Date
- 2018-08-29
- Lead Sponsor
- Jordan F. Karp
- Target Recruit Count
- 31
- Registration Number
- NCT02176291
- Locations
- 🇺🇸
Western Psychiatric Institute and Clinic, University of Pittsburgh, Pittsburgh, Pennsylvania, United States
Analgesic Response to Opioid Analgesics in Buprenorphine-Maintained Individuals
- First Posted Date
- 2014-05-13
- Last Posted Date
- 2014-05-13
- Lead Sponsor
- University of California, Los Angeles
- Target Recruit Count
- 12
- Registration Number
- NCT02136784
- Locations
- 🇺🇸
UCLA Integrated Substance Abuse Programs Outpatient Clinical Research Center, Los Angeles, California, United States
Drug Interaction & Methadone & Buprenorphine
- Conditions
- Interventions
- First Posted Date
- 2014-01-27
- Last Posted Date
- 2014-06-17
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 32
- Registration Number
- NCT02045693
- Locations
- 🇺🇸
Cri Lifetree, Philadelphia, Pennsylvania, United States
🇺🇸Anaheim Clinical Trials Llc, Anaheim, California, United States
🇺🇸Lifetree Clinical Research, Salt Lake City, Utah, United States
Multiple Dose Study of Blockade of Opioid Effects by Injections of Buprenorphine in Participants With Opioid Disorder
- Conditions
- Interventions
- First Posted Date
- 2014-01-23
- Last Posted Date
- 2018-04-24
- Lead Sponsor
- Indivior Inc.
- Target Recruit Count
- 39
- Registration Number
- NCT02044094
- Locations
- 🇺🇸
Vince & Associates Clinical Research, Overland Park, Kansas, United States
Compare the Efficacy and Safety of Norspan to Tramadol/Acetaminophen With Prolonged Postoperative Pain (PASSION)
- First Posted Date
- 2013-11-13
- Last Posted Date
- 2016-07-11
- Lead Sponsor
- Mundipharma Korea Ltd
- Target Recruit Count
- 136
- Registration Number
- NCT01983111
- Locations
- 🇰🇷
Sanggye Paik Hospital, Dept. of Orthopedic Surgery, Seoul, Korea, Republic of
Prospective Longitudinal Observational Study to Evaluate the Clinical Characteristics and Opioids Treatments in Patients With Breakthrough Cancer Pain
- First Posted Date
- 2013-09-19
- Last Posted Date
- 2016-04-14
- Target Recruit Count
- 150
- Registration Number
- NCT01946555
- Locations
- 🇮🇹
A.O. Universitaria Parma, Parma, Italia, Italy
🇮🇹Ospedale di Piacenza, Piacenza, Italy
🇮🇹Ospedale Magati, Scandiano, Italia, Italy
Efficacy of BNX Sublingual Tablets Versus BNX Sublingual Film for Treatment of Opioid-Dependent Adults
- Conditions
- Interventions
- First Posted Date
- 2013-07-26
- Last Posted Date
- 2017-05-10
- Lead Sponsor
- Orexo AB
- Target Recruit Count
- 759
- Registration Number
- NCT01908842
Evaluation of the Tolerability of Switching Subjects on Chronic ATC Opioid Therapy to Buprenorphine HCl Buccal Film
- Conditions
- Interventions
- First Posted Date
- 2013-06-06
- Last Posted Date
- 2017-02-27
- Lead Sponsor
- BioDelivery Sciences International
- Target Recruit Count
- 39
- Registration Number
- NCT01871285
- Locations
- 🇺🇸
CRI Lifetree (Lifetree Clinical Research), Salt Lake, Utah, United States
🇺🇸CRI Lifetree, Philadelphia, Pennsylvania, United States
🇺🇸Vince and Associates Clinical Research, Inc., Overland Park, Kansas, United States
Effects of Rifampicin on the Pharmacokinetics and Pharmacodynamics of Sublingual and Intravenous Buprenorphine
- First Posted Date
- 2013-05-15
- Last Posted Date
- 2014-11-20
- Lead Sponsor
- Turku University Hospital
- Target Recruit Count
- 12
- Registration Number
- NCT01854489
- Locations
- 🇫🇮
Turku University Hospital, Turku, Finland
Study to Assess Efficacy and Safety of BNX Sublingual Tablets for the Induction of Treatment of Opioid Dependence
- Conditions
- Interventions
- First Posted Date
- 2013-05-07
- Last Posted Date
- 2017-05-10
- Lead Sponsor
- Orexo AB
- Target Recruit Count
- 313
- Registration Number
- NCT01848054
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.